After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

The Delaware court ruled that Viatris’ drug does not infringe the "administered without another therapeutic agent" limitation ...

Viatris offers value with high free cash flow and dividends but faces growth challenges from legacy drug price erosion and ...

Shares of medication company Viatris (NASDAQ:VTRS) fell 3.8% in the afternoon session after its experimental therapy for blepharitis, an inflammatory condition of the eyelids, failed to meet the main ...

Viatris (Nasdaq: VTRS), a global healthcare company, today announced that five abstracts from its Phase 3 program evaluating novel fast-acting formulation of meloxicam (MR-107A-02) in ...

Aurobindo, Cipla and Viatris will develop, manufacture and supply long-acting injectable cabotegravir. Aurobindo, Cipla and ...

Valued at a market cap of $10.8 billion, Viatris Inc. (VTRS) is a healthcare company headquartered in Canonsburg, ...

A recently launched video series from the Biotechnology Innovation Organization (BIO) seeks to show how biotech may be able ...

Viatris reported that its MR-139 ophthalmic ointment failed to meet its primary endpoint in a Phase III blepharitis trial, ...

Viatris's phase 3 trial for pimecrolimus 0.3% in blepharitis failed to meet its primary endpoint of debris resolution after ...

Pairing Viatris' debt reduction with a slight uptick in EBITDA is why analysts expect the debt to EBITDA ratio will drop significantly, from 3.3 in 2021 to 2.4 by the end of next year.

Viatris is a relatively new company that started trading on Nov. 17, 2020. The entity was formed when pharma giant Pfizer spun off its off-patent medicine unit Upjohn, which merged with the ...